Compare
Cognition Therapeutics Inc vs Sangamo Therapeutics, Inc vs Cardiff Oncology, Inc. vs Passage BIO, Inc.
| Latest fiscal year | Cognition Therapeutics Inc CGTX | Sangamo Therapeutics, Inc SGMOQ | Cardiff Oncology, Inc. CRDF | Passage BIO, Inc. PASG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $39.55M | $593.0K | n/a |
| Revenue growth (YoY) | n/a | -31.6% | -13.2% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -306.5% | n/m | n/a |
| Net margin | n/a | -310.8% | n/m | n/a |
| Net income | -$23.49M | -$122.93M | -$45.85M | -$45.52M |
| EPS (Diluted) | -$0.32 | -$0.44 | -$0.69 | -$14.35 |
| Operating cash flow | -$24.59M | -$97.21M | -$37.92M | -$31.51M |
| Free cash flow | n/a | -$97.31M | -$37.97M | n/a |
| Cash & equivalents | $36.81M | $20.95M | $17.47M | $46.30M |
| Total assets | $48.39M | $59.74M | $61.88M | $62.28M |
| Total liabilities | $14.12M | $74.01M | $16.50M | $43.53M |
| Shareholders' equity | $34.27M | -$14.27M | $45.39M | $18.75M |
| Return on year-end equity | -68.5% | n/a | -101.0% | -242.7% |
| Shares outstanding | 88.90M | 350.69M | 68.31M | 3.18M |
Revenue, most recent five fiscal years
| Fiscal year | Cognition Therapeutics Inc | Sangamo Therapeutics, Inc | Cardiff Oncology, Inc. | Passage BIO, Inc. |
|---|---|---|---|---|
| Latest | n/a | $39.55M Ended 2025-12-31 | $593.0K Ended 2025-12-31 | n/a |
| 1 year earlier | n/a | $57.80M Ended 2024-12-31 | $683.0K Ended 2024-12-31 | n/a |
| 2 years earlier | n/a | $176.23M Ended 2023-12-31 | $488.0K Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | $111.30M Ended 2022-12-31 | $386.0K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $110.70M Ended 2021-12-31 | $359.0K Ended 2021-12-31 | n/a |